NBP
NASDAQ
US
NovaBridge Biosciences - American Depositary Shares
$2.43
▼ $-0.03
(-1.22%)
Vol 1.5M
4
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$458.9M
ROE
-11.5%
Margin
-439.8%
D/E
0.00
Beta
1.07
52W
$4–$5
Wall Street Consensus
9 analysts · Apr 20263
Strong Buy
5
Buy
1
Hold
0
Sell
0
Strong Sell
88.9%
Buy Rating
Price Chart
Similar Stocks
RZLT
Rezolute Inc
$218.8M
OVID
Ovid Therapeutics Inc
$116.1M
FHTX
Foghorn Therapeutics Inc
$305.4M
ORGO
Organogenesis Holdings Inc
P/E 654.1
$657.4M
AVXL
Anavex Life Sciences Corp
$318.1M
TARA
Protara Therapeutics Inc
$275.2M
CCCC
C4 Therapeutics Inc
$185.1M
ABEO
Abeona Therapeutics Inc
P/E 3.5
$285.6M
Earnings
Beat rate: 40.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Sep 2025 | $-0.05 | $-0.03 | +$0.02 |
| Jun 2025 | $-0.04 | $-0.07 | $-0.03 |
| Mar 2025 | $-0.07 | $-0.03 | +$0.04 |
| Dec 2024 | $-0.06 | $-0.08 | $-0.02 |
Fundamentals Trend
| Metric | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -39.2% | -1.9% | -3.4% | -18.5% | -18.5% | -11.5% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | — | — | — | -439.8% | -439.8% |
| Gross Margin | — | — | — | — | 100.0% | 100.0% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 15.67 | 20.95 | 22.35 | 22.82 | 22.86 | 14.47 |
Key Ratios
ROA (TTM)
-10.8%
P/S (TTM)
9.70
EPS (TTM)
$-0.12
Rev Growth 3Y
-73.8%
52W High
$5.14
52W Low
$3.60
$3.60
52-Week Range
$5.14
How does NBP compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
NBP valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
9.7
▼
25%
below
peers
(12.9)
vs Peers
vs Industry
Pricier
P/B ratio
—
▼
0%
below
peers
(2.5)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
NBP profitability vs Biotechnology peers
ROE
-11.5%
▲
83%
above
peers
(-67.3%)
vs Peers
vs Industry
Top tier
Net margin
-439.8%
▼
53%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
100.0%
▲
27%
above
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
-10.8%
▲
77%
above
peers
(-46.7%)
vs Peers
vs Industry
Top tier
NBP financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
14.5
▲
226%
above
peers
(4.4)
vs Peers
vs Industry
Strong liquidity
Beta
1.1
▲
11%
above
peers
(1.0)
vs Peers
vs Industry
Less volatile
NBP fundamentals radar
NBP
Peer median
Industry
NBP profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio